New NxStageÃ‚® FREEDOM Data Shows Continued, Marked Benefits for Patients Using the System Oneâ„¢ for Daily Home Hemodialysis Throughout a 12 Month Period(2)
LAWRENCE, Mass. and PHOENIX, Feb. 20, 2011 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced the latest interim results from its ongoing FREEDOM study which show an increase in overall quality of life benefits, significant improvement in overall sleep quality and a marked improvement in Restless Legs Syndrome (RLS) symptoms experienced by patients after 12 months of daily home hemodialysis with the NxStage System One™. The study results were presented during the Annual Dialysis Conference in Phoenix, Arizona. The ongoing FREEDOM study is the largest study of its kind to measure the clinical and economic benefits of daily home hemodialysis treatment, as compared to conventional, thrice-weekly in-center hemodialysis treatment for patients requiring dialysis therapy.
"These latest 12-month results are extremely encouraging. The analysis shows the quality of life benefits eligible patients experience at month four continue and sometimes strengthen by month 12. These benefits are dramatic and can be truly life-changing," said Dr. Frederic Finkelstein MD, Chief of Nephrology at the Hospital of St. Raphael in New Haven, Conn. and Clinical Professor of Medicine at Yale University Medical School as well as an investigator on the FREEDOM study. "These improvements in mental and physical scores suggest that daily hemodialysis leads to an overall healthier and happier patient."
The interim analysis of the FREEDOM study shows that daily home hemodialysis is associated with clear improvements in quality of life benefits sustained throughout a 12-month period, as measured by the SF-36v2 Health Survey. Results show:Significant improvements in both mental health scores (Mental Component Summary) and physical health scores (Physical Component Summary)